NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.02 Million USD | 31.46% |
| 2022 | -1.49 Million USD | -71.82% |
| 2021 | -870.28 Thousand USD | -40.6% |
| 2020 | -618.99 Thousand USD | -41.85% |
| 2019 | -436.36 Thousand USD | -113.23% |
| 2018 | -204.64 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - USD | 100.0% |
| 2024 Q1 | -114.91 Thousand USD | -106.07% |
| 2023 Q4 | 1.89 Million USD | 812.52% |
| 2023 Q3 | -265.54 Thousand USD | 33.65% |
| 2023 Q1 | -394.5 Thousand USD | 6.79% |
| 2023 Q2 | -400.23 Thousand USD | -1.45% |
| 2023 FY | -1.02 Million USD | 31.46% |
| 2022 Q3 | -326.19 Thousand USD | 17.85% |
| 2022 Q2 | -397.05 Thousand USD | -13.82% |
| 2022 Q1 | -348.86 Thousand USD | -48.72% |
| 2022 FY | -1.49 Million USD | -71.82% |
| 2022 Q4 | -423.23 Thousand USD | -29.75% |
| 2021 Q1 | -174.33 Thousand USD | 0.0% |
| 2021 FY | -870.28 Thousand USD | -40.6% |
| 2021 Q4 | -234.57 Thousand USD | 2.55% |
| 2021 Q3 | -240.7 Thousand USD | -11.35% |
| 2021 Q2 | -216.16 Thousand USD | -24.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | -618.99 Thousand USD | -41.85% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -436.36 Thousand USD | -113.23% |
| 2018 FY | -204.64 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 707.974% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -309.989% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -86.02% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -475.827% |
| Better Therapeutics, Inc. | -2.72 Million USD | 62.441% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 25.995% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 342.475% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 95.528% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -0.341% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 85.547% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -295.742% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -1844.992% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 63.34% |
| Molecular Templates, Inc. | 50.39 Million USD | 102.034% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -759.191% |
| Orgenesis Inc. | -5.72 Million USD | 82.097% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 96.004% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -22177.157% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 103.488% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -109.9% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -341.798% |
| Trevena, Inc. | 1.45 Million USD | 170.445% |
| Vaxxinity, Inc. | -2.23 Million USD | 54.119% |
| Vaccinex, Inc. | -16 Million USD | 93.596% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -108.328% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 8928.355% |